Exosomes as a Surrogate Marker for Autophagy in Peripheral Blood, Correlative Data from Phase I Study of Chloroquine in Combination with Carboplatin/Gemcitabine in Advanced Solid Tumors

Nagla Abdel Karim(University of Cincinnati), John C. Morris(University of Cincinnati)

Asian Pacific Journal of Cancer Prevention

December 1, 2019

10.31557/apjcp.2019.20.12.3789

Cited by 6

Related Papers

Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells

|BMC Cancer|2018|131

Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy

|Frontiers in Oncology|2021|26

Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).

|Journal of Clinical Oncology|2019|8

A Phase I Trial to Determine the Safety and Tolerability of Autophagy Inhibition Using Chloroquine or Hydroxychloroquine in Combination with Carboplatin and Gemcitabine in Patients with Advanced Solid Tumorsced solid tumors.

|Asian Pacific Journal of Cancer Prevention|2025|3